Trial Profile
A Multicenter Trial of Autologous Bone Marrow Mononuclear Cells for the Treatment of Adult Severe Traumatic Brain Injury
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs CEVA 101 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 15 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 May 2024.
- 15 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Apr 2024.
- 15 Jul 2023 Status changed from recruiting to active, no longer recruiting.